Vaxxinova, based in Wilmar, MN, has joined the National Chicken Council as an allied member company. Mark Mahaffey, Key Account Manager, will serve as the official representative to NCC.
Vaxxinova US is dedicated to advancing animal health through the development of veterinary biologics and customized services designed to support the food animal industry. The company develops, manufactures, and sells veterinary vaccines based upon its commitment to autogenous vaccines and its proprietary technologies.
At the heart of Vaxxinova’s innovation is its patented Siderophore Receptors and Porins (SRP) technology and proprietary Newport Laboratories whole cell biologics. These technologies are backed by a proprietary manufacturing process that incorporates unique adjuvants, found only in Vaxxinova products.
The SRP technology targets essential bacterial components—Siderophore Receptors and Porins—which are responsible for transporting iron, a vital nutrient for bacterial survival. By triggering the host’s immune system to produce antibodies against these components, the vaccine effectively deprives harmful bacteria of iron, leading to their death. Because SRPs are highly conserved across many bacterial strains, this approach offers broad protection.
To learn more about Vaxxinova, visit their website here.
